FDA: Product quality issues fuel rise in drug shortages

"A very large number of quality product issues" is what Valerie Jensen, associate director for FDA's drug shortage program (CDER), cites as the major cause of the 178 shortages counted by the regulator in 2010. To be precise, product quality played a role in 54% of shortages. Some of the issues were sterility or impurities; others were production delays or capacity problems. "In 2011, we're seeing the same trend." Story

Suggested Articles

While no shortages of drug supplies have been reported, governments are trying to get a handle on what they can do if they materialize.

Branded drug sales in China could suffer in the short term as marketing activities for new meds are limited to reduce the risk of contagion.

Korean CDMO Samsung Biologics is expanding and China API maker WuXi STA opened a 30,000-square-foot oligonucleotide manufacturing facility.